Ads
related to: trelegy for copd- Sign Up
Sign Up To Stay Informed
Register To Receive News & Updates
- Resources
Useful Information
And Materials
- Access and Coverage
See Insurance And
Coverage Information
- Learn More
Quick Facts
About COPD
- Sign Up
Search results
COPD Doesn’t Have To Hold You Back – Here’s What To Do After Being Diagnosed
Parade via Yahoo News· 6 months agoMore than 15 million people in the U.S. are affected by COPD (chronic obstructive pulmonary...
COPD patients see promise of new therapies to ease discomfort, aid breathing
United Press International via Yahoo News· 7 months agoRecent advances in chronic obstructive pulmonary disease offer patients more hope in easing...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
Zacks via Yahoo Finance· 3 months agoWe expect GSK plc. GSK to beat expectations when it reports fourth-quarter and full-year 2023...
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 1 month agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
GSK to cap out-of-pocket inhaler costs in US
Reuters via Yahoo News· 1 month agoThe cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and...
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoGSK plc. GSK will report first-quarter 2023 results on Apr 26, before the opening bell. In the last...
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
Zacks via Yahoo Finance· 2 years agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoThank you for joining us to review Royalty Pharma's second quarter 2022 results. All forward-looking...
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
Zacks via Yahoo Finance· 1 year agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...
Ads
related to: trelegy for copd
